<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34894926</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7-8</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Therapeutic effect of a novel curcumin derivative GT863 on a mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>489</StartPage><EndPage>495</EndPage><MedlinePgn>489-495</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.2012699</ELocationID><Abstract><AbstractText>The present study investigated the therapeutic effects of the curcumin derivative 3-[(1E)-2-(1H-indol-6-yl)ethenyl]-5-[(1E)-2-[2-methoxy-4-(2-pyridylmethoxy)phenyl]ethenyl]-1H-pyrazole (GT863) in amyotrophic lateral sclerosis (ALS). The inhibitory effect of GT863 on superoxide dismutase 1 (SOD1) aggregation was evaluated in cell-free assays. GT863 interfered with the conformational changes of the SOD1 protein and later, oligomeric aggregation. Furthermore, its antioxidant, anti-inflammatory, and neuroprotective effects were evaluated in cell-free and cultured cell assays. GT863 inhibited H<sub>2</sub>O<sub>2</sub>- and glutamate-induced cytotoxicity and activated an antioxidant responsive element pathway. Additionally, <i>in&#xa0;vivo</i> effects of GT863 in the ALS mice model were evaluated by its oral administration to H46R mutant SOD1 transgenic mice. Rotarod test showed that GT863 administration significantly slowed the progression of motor dysfunction in the mice. In addition, GT863 substantially reduced highly-aggregated SOD1, further preserving large neurons in the spinal cord of GT863-treated mice. Collectively, these results indicated that GT863 could be a viable therapeutic agent with multiple vital actions for the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dentistry, Oral and Maxillofacial-Plastic and Reconstructive Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Hiroyasu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuda</LastName><ForeName>Michiaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Green Tech Co., Ltd, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koyama</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yasuhiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waku</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto-shi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iino</LastName><ForeName>Mitsuyoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dentistry, Oral and Maxillofacial-Plastic and Reconstructive Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Neuroscience and Sensory Organs, Tohoku University Graduate School of Medicine, Miyagi, Japan, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arawaka</LastName><ForeName>Shigeki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohta</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishizawa</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawasaki</LastName><ForeName>Kanan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urano</LastName><ForeName>Yasuomi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyasaka</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kume</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akaike</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>Hachiro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Green Tech Co., Ltd, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takeo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="Y">Curcumin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Superoxide dismutase 1 (SOD1)</Keyword><Keyword MajorTopicYN="N">aggregation inhibitor</Keyword><Keyword MajorTopicYN="N">curcumin derivative</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>13</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34894926</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.2012699</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>